Pfizer actively pursues mergers despite U.S. corporate hesitance

Pfizer is standing out in a complicated business landscape in America. The company, worth $220 billion, has been successful despite many challenges, including high-interest rates and heightened scrutiny from regulators. Their confidence comes partly from their profitable partnership with BioNTech during the pandemic. At their new headquarters in Hudson Yards, Pfizer executives are excited about mergers and acquisitions (M&A). They have spent $70 billion on deals in just over a year, including a significant purchase of Seagen, a cancer drug maker. Pfizer believes this strategy will help them boost revenues, even as sales from pandemic-related products start to decline. Unlike many other companies that are cautious due to economic uncertainty, Pfizer remains optimistic, especially about their business in China. They have continued to invest in their operations there and signed an agreement with a Chinese company to market several new drugs. This is a bold move amid current geopolitical tensions. However, Pfizer's stock has dropped by nearly 25% this year, and some analysts worry they may be overpaying for Seagen. They need to prove to investors that their plans will pay off in the long run, especially as they face potential challenges with drug pricing in the U.S. Overall, while many companies are hesitant, Pfizer is showing that taking calculated risks can lead to success. Their past decision to acquire Wyeth during the financial crisis is a reminder that bold moves can pay off in unexpected ways.